Trials / Conditions / Relapsed or Refractory Diffuse Large B-cell Lymphoma
Relapsed or Refractory Diffuse Large B-cell Lymphoma
6 registered clinical trials studyying Relapsed or Refractory Diffuse Large B-cell Lymphoma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (D NCT05144841 | Merck Sharp & Dohme LLC | Phase 2 |
| Withdrawn | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or NCT04607772 | Karyopharm Therapeutics Inc | Phase 1 / Phase 2 |
| Unknown | Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects NCT06074107 | BeBetter Med Inc | Phase 2 |
| Completed | A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL NCT04049825 | Otsuka Pharmaceutical Co., Ltd. | Phase 1 |
| Withdrawn | A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relap NCT04279938 | Royal Marsden NHS Foundation Trust | Phase 1 |
| Unknown | A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) NCT01676558 | Korea Cancer Center Hospital | Phase 2 |